Simplify Logo

Full-Time

Quality Control Microbiology Associate

Confirmed live in the last 24 hours

Adicet Bio, Inc

Adicet Bio, Inc

51-200 employees

Develops allogeneic gamma delta T cell therapies

Biotechnology
Healthcare

Compensation Overview

$91k - $126kAnnually

Entry, Junior

San Carlos, CA, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • BS in biological sciences or a related field is required.
  • 1-3 years of relevant academic and industry experience in a manufacturing environment.
  • Ability to operate for lengthy periods of time while gowned in cleanroom is expected.
  • High initiative, organized, and conscientious record keeping skills, strong attention to detail.
  • Excellent verbal and written communication skills.
  • Ability to utilize troubleshooting and problem-solving skills.
Responsibilities
  • Perform environmental monitoring (EM) in cleanrooms and controlled areas.
  • Complete documentation for QC activities including EM data, material preparation, equipment logs and inventory logs.
  • Draft and review data reports.
  • Perform microbial isolations and identifications.
  • Write and revise QC specific procedures.
  • Generate EM trend reports.
  • Write/participate in EM investigations, deviation, and CAPAs.
  • Maintenance of the laboratory, supplies, and equipment.

Adicet Bio develops cancer therapies using allogeneic gamma delta T cell therapies, which are immune cells designed to target and destroy cancer cells. Their approach utilizes donor-derived cells that are readily available, allowing for faster treatment compared to traditional methods that require a patient's own cells. The company focuses on serving healthcare providers, hospitals, and research institutions involved in cancer treatment. Adicet Bio's business model includes developing and commercializing its proprietary therapies, generating revenue through product sales and licensing agreements. A recent merger with resTORbio aims to enhance their technology and accelerate development. With significant funding, Adicet Bio is positioned to improve cancer treatment outcomes through its unique immunotherapy approach.

Company Stage

IPO

Total Funding

$243.6M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

-7%

2 year growth

35%
Simplify Jobs

Simplify's Take

What believers are saying

  • Adicet Bio's strong financial position, with $247.6 million in cash and cash equivalents, provides a solid foundation for continued R&D and clinical trials.
  • The promising preclinical data on ADI-270 and the initiation of multiple Phase 1 trials highlight the company's robust pipeline and potential for breakthrough therapies.
  • The company's strategic focus on both solid and hematological cancers, as well as autoimmune diseases, increases the likelihood of successful treatments and market adoption.

What critics are saying

  • The clinical and regulatory landscape for new cancer therapies is highly competitive and uncertain, posing risks to Adicet Bio's market entry and adoption.
  • The reliance on successful clinical trial outcomes for ADI-001 and ADI-270 introduces significant uncertainty and potential delays in commercialization.

What makes Adicet Bio, Inc unique

  • Adicet Bio's use of allogeneic gamma delta T cells offers an 'off-the-shelf' solution, providing faster and potentially more effective cancer treatments compared to autologous therapies.
  • The company's focus on both cancer and autoimmune diseases broadens its market reach and potential impact, unlike competitors who may focus solely on one area.
  • Adicet Bio's recent merger with resTORbio and significant funding rounds, including an $80 million Series B, bolster its R&D capabilities and accelerate its path to commercialization.